Mereo BioPharma Group plc

Annual Trend FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Revenue $36.5m
$0 -100.00%
$10.0m
$0 -100.00%
$500k
$500k 0.00%
Cost of Goods and Services Sold $17.9m
($936k) -105.23%
$4.9m +624.70%
$0 -100.00%
$246k
$133k -45.84%
Cost of revenue ($17.9m)
$936k +105.23%
$2.6m +175.00%
$0 -100.00%
$133k
$133k 0.00%
Net Interest Income ($750k)
$1.7m +322.80%
$1.9m +14.78%
$1.7m -8.97%
Gross Profit $18.6m
$35.5m +91.46%
$7.4m -79.10%
$0 -100.00%
$367k
$367k 0.00%
Research And Development $34.6m $22.7m $23.6m $16.3m $23.6m $25.0m $17.4m $20.9m $17.8m $18.6m
Research and development expenses ($34.6m) ($22.7m) ($23.6m) ($16.3m) ($23.6m) ($25.0m) $18.6m
General and Administrative Expense $18.4m $26.4m $23.0m $19.8m
Amortization of Intangible Assets $395k $438k $465k
Operating expenses:
Operating Costs and Expenses $700k $700k $700k
Other Operating Expenses ($1.3m) ($1.6m) ($2.1m)
Other Operating Income Expense ($45.3m) ($34.5m) ($39.5m) ($37.6m) ($20.9m) $811k ($27.1m) ($41.9m) ($41.6m)
Operating Income (Loss) ($45.3m)
($34.5m) +23.90%
($39.5m) -14.62%
($37.6m) +4.93%
($20.9m) +44.27%
($43.6m) -108.11%
($28.4m) +34.78%
($47.4m) -66.68%
($40.1m) +15.32%
($35.9m) +10.46%
Interest Expense $2.9m $1.4m $255k $95k
Interest Expense On Lease Liabilities $1.3m $1.1m $227k $209k $95k
Interest Income, Operating $104k $1.8m
Interest Income $2.1m $3.0m $2.2m $1.8m
Net Non Operating Interest Income Expense ($750k) $1.7m $1.9m $1.7m
Foreign Currency Transaction Gain (Loss), before Tax ($2.3m) $1.2m ($6.3m)
Gain On Sale Of PPE $153k $0 $0
Gain On Sale Of Security ($2.1m) $791k ($5.5m) ($1.5m)
Gain (Loss) on Derivative Instruments, Net, Pretax $245k ($419k) $805k
Other Income $300k
Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method $1.0m
Other Nonoperating Income (Expense) ($10k) $0 $300k
Other Income Expense ($2.1m) $791k ($5.5m) ($1.5m)
Pre-Tax Income ($30.0m) ($43.3m) ($41.9m) ($35.7m)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest ($30.0m) ($43.3m) ($41.9m) ($35.7m)
Current Tax Expense (Income) $1.5m ($601k)
Deferred Tax Expense (Income) Recognised In Profit Or Loss $3k
Current Income Tax Expense (Benefit) $532k $0 $0 $0
Income Tax Expense Continuing Operations ($8.2m) ($5.3m) ($6.3m) ($2.8m) $1.5m ($1.9m) $0
Net Income From Continuing And Discontinued Operation ($29.5m) ($43.3m) ($41.9m) ($35.7m)
Earnings Per Share, Basic ($0.39) ($0.48) $0.02 ($0.06) ($0.04) ($0.06) ($0.05) ($0.20)
Earnings Per Share, Diluted ($0.56) ($0.45) ($0.39) ($0.48) ($0.05) ($0.06) ($0.04) ($0.06) ($0.05) ($0.20)
Basic Earnings (Loss) Per Share ($0.39) ($0.48) $0.02 ($0.06) ($0.20) ($0.30) ($0.25) ($0.20)
Diluted Earnings (Loss) Per Share ($0.56) ($0.45) ($0.39) ($0.48) ($0.05) ($0.06) ($0.04) ($0.06) ($0.05) ($0.20)
Weighted Average Number of Shares Outstanding, Basic 659.5m 739.6m 797.1m 160.3m
Basic Average Shares $131.9m $147.9m $159.4m $160.3m
Diluted Average Shares $131.9m $147.9m $159.4m $160.3m
Weighted Average Number of Shares Outstanding, Diluted 659.5m 739.6m 797.1m 160.3m
Additional Financial Items
Applicable Tax Rate $0 $0
Depreciation Right of Use Assets $1.5m $1.5m $570k $583k
Finance Income $827k $307k $377k $44k $1k $696k
Income (Loss) Attributable to Parent, before Tax $30.0m $43.3m ($41.9m)
Profit Loss Attributable To Owners Of Parent ($38.8m) ($32.0m) ($34.8m) ($163.6m) $12.7m ($34.2m)
Profit Loss Before Tax ($47.0m) ($37.3m) ($41.1m) ($166.4m) $14.2m ($36.1m)
Profit Loss From Operating Activities ($45.3m) ($35.2m) ($39.5m) ($37.6m) ($20.9m) ($43.6m)
Changes in the fair value of financial instruments $716k $875k ($109.8m) $40.0m $7.8m
Gain/(loss) on disposal of intangible assets ($10.9m) $113k
Net foreign exchange gain/(loss) ($1.4m) ($44k) $483k ($1.8m) ($954k) $1.5m
(Loss)/profit before tax ($47.0m) ($37.3m) ($41.1m) ($166.4m) $14.2m ($36.1m)
Taxation $8.2m $5.3m $6.3m $2.8m ($1.5m) $1.9m
(Loss)/profit for the year, attributable to equity holders of the parent ($38.8m) ($32.0m) ($34.8m) ($163.6m) $12.7m ($34.2m)
Currency translation of foreign operations ($499k) $349k ($191k) ($1.8m)
Average Dilution Earnings ($52.0m) $0 $0
Diluted EPS ($0.20) ($0.30) ($0.25) ($0.20)
Diluted NI Availto Com Stockholders ($29.5m) ($43.3m) ($41.9m) ($35.7m)
Normalized EBITDA ($24.0m) ($41.6m) ($34.9m) ($34.4m)
Normalized Income ($27.4m) ($44.0m) ($36.3m) ($34.2m)
Other Gand A $18.4m $26.4m $23.0m
Reconciled Depreciation $1.1m $1.1m $1.1m $1.2m
Selling General And Administration $18.4m $26.4m $23.0m
Special Income Charges $153k $0 $82k
Tax Effect Of Unusual Items ($38k) $0 $0 $0
Tax Provision ($532k) $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Administrative Expense $10.7m $12.5m $15.9m $21.2m $15.9m $19.5m
Employee Benefits Expense $9.3m $6.2m $8.0m $10.7m $12.2m $14.2m
Expense From Share-Based Payment Transactions With Employees $3.7m $2.2m $1.6m $1.6m $3.3m $3.9m
Finance Costs $1.1m $2.4m $3.5m $6.4m $4.0m $3.4m
Administrative expenses ($10.7m) ($11.8m) ($15.9m) ($21.2m) ($15.9m) ($19.5m)
Operating Expense $34.6m $45.7m $38.6m $36.4m
Total comprehensive (loss)/income for the year, attributable to equity holders of the parent ($38.8m) ($32.0m) ($35.3m) ($163.3m) $12.5m ($36.0m)
Total Unusual Items ($2.1m) $791k ($5.5m) ($1.5m)
Total Expenses $37.1m $45.7m $38.8m $36.4m
Total Other Finance Cost $28k $50k $45k